E!7991 Fecal-Calprotectin Getica AB

Important results from the project

A high speed turbidimetric calprotectin assay with improved fecal samples and fecal extractive robotics has utväcklast during the project. It will improve patient diagnosis and generate significant cost savings for the medical community. Fecal calprotectin is a great differentiator for IBS (Irritable Bowel Syndrome) and IBD (Intestinal Bowel Disease). The differentiation between IBS and IBD are currently using slower methods. This is the first international turbidimetriske automated measuring method for faecal samples.

Expected long term effects

A turbidimetric assay has the potential for significant cost savings for the medical community. A high rate turbidimetric method works on all modern routine clinical chemistry platforms available in hospitals and commercial laboratories. University Partners conducted studies to support and document the new method. A robotic system for faster and more hygienic handling of feces and fecal extracts developed, tested and verified. Getica AB has developed and produced - and will produce - calprotectin antigen and antibodies.

Approach and implementation

ENGELSK The project has been developed with Gentian turbidimetric basic technology, with Getica antigen and anti body technology, and using Buhlmann markedsaparat and clinical contacts. Robotic handling of stool samples has been developed in collaboration with the Karolinska Hospital. Clinical collaboration with Uppsala University Hospital laid the foundation for rapid marketsintruduksjon and international product sales are now underway, and will provide the basis for growth in Getica AB